Creative Biolabs has invited Dr. Markita Landry to walk us through how her team developed a near Infrared Catecholamine nanosensor (nIRCat) and used real-time imaging to find out what drives late-disease decreases in evoked dopamine release, and how to use these findings as optimal therapeutic intervention timepoints for siRNA-based Huntington's disease therapies.